Neutropenia and antibiotics: when, what, how and why?-Reference-Cited by-同舟云学术

Neutropenia and antibiotics: when, what, how and why?

Published:2023-06-12 Issue:4 Volume:36 Page:218-227
ISSN:0951-7375
Container-title:Current Opinion in Infectious Diseases
language:en
Short-container-title:

Author:

Dickter Jana¹,Logan Cathy²,Taplitz Randy¹

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, City of Hope National Medical Center, Duarte

2. Division of Infectious Diseases and Global Health, University of California, San Diego, La Jolla, CA, USA

Abstract

Purpose of review Our aim is to review recent literature on antibiotic use in patients with neutropenia. Recent findings Prophylactic antibiotics are associated with risks and have limited mortality benefit. While early antibiotic use in febrile neutropenia (FN) is critical, early de-escalation or discontinuation may be safe in many patients. Summary With an increasing understanding of potential risks and benefits of use and improved risk assessment, paradigms of antibiotic use in neutropenic patients are changing.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Microbiology (medical)

Reference50 articles.

1. Optimal management of neutropenic fever in patients with cancer;Zimmer;J Oncol Pract,2019

2. Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials;Kimura;J Infect,2014

3. Can consideration of the microbiome improve antimicrobial utilization and treatment outcomes in the oncology patient?;Galloway-Peña;Clin Cancer Res,2017

4. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease;Staffas;Blood,2017

5. The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation;Khuat;Gut Microbes,2021